Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu177-PSMA theranostic treatment for recurrent glioblastoma
IRCT20241005063266N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium (177Lu) PSMA in glioblastoma (GBM), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Tumor uptake before and after treatment, MRI findings before and after treatment and 4 more. Started Nov 2024; status: completed.
02
Drugs
lutetium (177Lu) PSMA
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on IRCT20241005063266N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241005063266N1.